Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 25 , ISSUE 8 ( August, 2021 ) > List of Articles


The Use of an Interleukin-6 Inhibitor in Vasoplegic Shock from Severe Systemic Inflammatory Response Syndrome: A Case Report

Wiaam Y Elkhatib, Hollie Saunders, Scott A Helgeson, John E Moss

Keywords : Cardiopulmonary bypass, Chronic myelomonocytic leukemia, Coronary artery bypass grafting, Cytokine release syndrome, Systemic inflammatory response syndrome, Tocilizumab

Citation Information : Elkhatib WY, Saunders H, Helgeson SA, Moss JE. The Use of an Interleukin-6 Inhibitor in Vasoplegic Shock from Severe Systemic Inflammatory Response Syndrome: A Case Report. Indian J Crit Care Med 2021; 25 (8):939-941.

DOI: 10.5005/jp-journals-10071-23943

License: CC BY-NC 4.0

Published Online: 12-08-2021

Copyright Statement:  Copyright © 2021; The Author(s).


A 66-year-old Caucasian male with a history of chronic myelomonocytic leukemia (CMML) developed fluid-unresponsive hypotension requiring initiation of four different maximum dosed vasopressors, steroids, and broad-spectrum antibiotics 4 hours following four-vessel coronary artery bypass grafting involving a 150-minute cardiac bypass. Placement of a Swanz-Ganz catheter showed a cardiac output of 7 L/minute with systemic vascular resistance of 571 dynes/sec/cm−5. Over 24 hours, three doses of tocilizumab (interleukin-6 inhibitor) every 8 hours were initiated, plus 250 mg methylprednisolone per 6 hours increment, and then daily thereafter. After the initial dose of tocilizumab, it was possible to wean vasoconstrictors. We have shown for the first time that therapy with tocilizumab is effective in reversing the hemodynamic instability associated with the significant systemic inflammatory response from the “double hit” of CMML and coronary artery bypass grafting with cardiopulmonary bypass as has previously been shown in cytokine release syndrome.

  1. Patnaik MM, Tefferi A. Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management. Am J Hematol 2018;93(6):824–840. DOI: 10.1002/ajh.25104.
  2. Feng Y, Li X, Cassady K, Zou Z, Zhang X. TET2 function in hematopoietic malignancies, immune regulation, and DNA repair. Front Oncol 2019;9:210. DOI: 10.3389/fonc.2019.00210.
  3. Passaroni AC, Felicio ML, Campos NLKL, Silva MAM, Yoshida WB. Hemolysis and Inflammatory response to extracorporeal circulation during on-pump CABG: comparison between roller and centrifugal pump systems. Braz J Cardiovasc Surg 2018;33(1):64–71. DOI: 10.21470/1678-9741-2017-0125.
  4. Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M. Cytokine release syndrome. J ImmunoTher Cancer 2018;6(1):56. DOI: 10.1186/s40425-018-0343-9.
  5. Moat NE, Shore DF, Evans TW. Organ dysfunction and cardiopulmonary bypass: the role of complement and complement regulatory proteins. Eur J Cardiothorac Surg 1993;7(11):563–573. DOI: 10.1016/1010-7940(93)90241-3.
  6. Halter J, Steinberg J, Fink G, Lutz C, Picone A, Maybury R, et al. Evidence of systemic cytokine release in patients undergoing cardiopulmonary bypass. JECT 2005;37(3):272–277. PMID: 16350379; PMCID: PMC4680784.
  7. Patel AB, Pettijohn EM, Abedin SM, Raps E, Deininger MW. Leukemoid reaction in chronic myelomonocytic leukemia patients undergoing surgery: perioperative management recommendations. Blood Adv 2019;3(7):952-955. DOI: 10.1182/bloodadvances.2019032300.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.